Fosfomax3 gm/sachet

Fosfomax is a broad-spectrum, bactericidal antibiotic belonging to the phosphonic acid derivative class. Its clinical use varies by evidence strength:

Established / Approved Use

• Uncomplicated urinary tract infection (acute cystitis) in women caused by susceptible Escherichia coli or Enterococcus faecalis — this is the primary FDA-approved indication for the oral (tromethamine) formulation, given as a single dose.

Guideline-Supported / Specialist Use

• An intravenous form (Fosfomax disodium/injection) is used in hospital settings for complicated urinary tract infections, including cases caused by multidrug-resistant organisms, under specialist supervision.
• Used as part of combination therapy for selected multidrug-resistant Gram-negative or Gram-positive infections (e.g., resistant E. coli, Pseudomonas aeruginosa, or MRSA) when guided by culture and sensitivity results.

Off-Label Use

• Repeated-dose oral regimens (e.g., every 3 days for 3 doses) are sometimes used off-label for UTI prophylaxis or in men, though this is not an FDA-approved regimen and should only be done under medical supervision.

Fosfomax is not indicated for pyelonephritis, perinephric abscess, or systemic/bloodstream infections when used as the single-dose oral formulation.

The oral formulation of Fosfomycin is supplied as fosfomycin tromethamine granules for oral solution, most commonly as a sachet containing the equivalent of 3 grams of fosfomycin (approximately 5.631 g of fosfomycin tromethamine salt), along with inactive ingredients such as flavoring agents, saccharin, and sucrose.

An intravenous form, fosfomycin disodium/fosfomycin for injection, is also available in some countries as a powder for reconstitution for hospital use.

Fosfomax is a synthetic, broad-spectrum bactericidal antibiotic and the first agent in the phosphonic acid derivative class. It is structurally unrelated to other antibiotic classes, which limits cross-resistance with commonly used agents.

It is best known worldwide as a convenient single-dose oral treatment for uncomplicated urinary tract infections in women, marketed in Bangladesh as an oral powder/granule sachet (Fosfomax trometamol, 3 g) under several brand names. An injectable disodium salt form also exists for more severe or resistant infections in hospital settings.

Fosfomax belongs to the phosphonic acid derivative class of antibiotics, a distinct urinary anti-infective class not chemically related to penicillins, cephalosporins, fluoroquinolones, or other common antibiotic groups.

Fosfomycin is bactericidal. It inactivates the bacterial enzyme enolpyruvyl transferase (MurA), irreversibly blocking an early step in bacterial cell wall (peptidoglycan) synthesis. It also reduces the ability of bacteria such as E. coli to adhere to the uroepithelial lining of the urinary tract, which may contribute to its clinical effect in cystitis.

Pharmacokinetics (oral tromethamine form)

• Absorption: Oral bioavailability is approximately 37% when taken fasting (slightly reduced with food).
• Distribution: Distributes into urine, kidney, bladder wall, prostate, and seminal vesicles; it also crosses the placenta.
• Elimination: Excreted largely unchanged by the kidneys into urine, achieving high urinary concentrations that persist for over 48 hours after a single dose — this is the basis of its single-dose efficacy in cystitis. Elimination half-life is prolonged in renal impairment.

Fosfomax granules must never be taken dry. Empty the entire contents of one sachet into a glass, dissolve in 3-4 ounces (approximately 90-120 mL) of cool water (not hot water), stir well, and drink immediately after dissolving.

• May be taken with or without food, though taking on an empty stomach may modestly improve absorption in some patients.
• Do not take a double or repeat dose to "boost" the effect — it is designed as a single-dose therapy for uncomplicated cystitis.
• If symptoms do not improve within 2-3 days, contact your physician rather than repeating the dose on your own.

Fosfomax has a limited number of well-documented clinically significant interactions:

• Metoclopramide (and other drugs that increase gastrointestinal motility): may lower serum and urinary concentrations of Fosfomax, potentially reducing its effectiveness. Concurrent use should be avoided when possible.
• Cimetidine: studies have not shown a clinically significant interaction with Fosfomax.

Always inform your physician or pharmacist of all medicines you are taking before starting Fosfomax.

Because Fosfomax for cystitis is usually given as a single dose, side effects are generally mild and self-limited.

Common (reported in more than 1% of patients)

• Diarrhea
• Nausea
• Headache
• Vaginitis
• Rhinitis

Rare but Serious

• Clostridioides difficile-associated diarrhea/colitis (can occur with any antibiotic, including after a single dose)
• Angioedema or other hypersensitivity/allergic reactions
• Aplastic anemia, hepatic necrosis, and optic neuritis (rare post-marketing reports)

Seek medical attention promptly for signs of severe allergic reaction (swelling of face/throat, difficulty breathing) or for severe or persistent diarrhea.

Pregnancy: Animal reproduction studies with Fosfomax have not shown teratogenic effects even at high doses, and it has traditionally been assigned to pregnancy category B in older labeling. However, human data remain limited, so Fosfomax should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Fosfomax is excreted in human breast milk. A decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue the drug, weighing the benefit of treatment against the potential risk to the infant.

• Antibiotic stewardship: Take Fosfomax exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• Clostridioides difficile-associated diarrhea (CDAD): Antibiotic use, including Fosfomax, has been associated with CDAD, ranging from mild diarrhea to fatal colitis. Seek medical advice if diarrhea develops during or after treatment.
• Not for complicated infections: Single-dose oral Fosfomax is intended only for uncomplicated cystitis; it should not be used for pyelonephritis, perinephric abscess, or systemic infections.
• Renal impairment: Reduced kidney function lowers urinary concentrations and may reduce effectiveness (see Contraindications for severe impairment).
• Complete the full course as directed even though symptoms may improve quickly after a single dose; consult your physician if symptoms persist or recur.

Reported human overdose experience with Fosfomax is limited; symptoms such as vestibular disturbance (dizziness/imbalance), impaired hearing, metallic taste, and a general decline in taste perception have been described. Animal studies at very high multiples of the therapeutic dose showed minimal toxicity.

If an overdose of Fosfomax is suspected, seek immediate medical attention or contact a poison control center/emergency services. Treatment is generally supportive and symptomatic; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Once the granules are dissolved in water, drink the solution immediately; do not store the prepared solution for later use.

• Renal impairment: Use with caution in mild-to-moderate impairment; contraindicated in severe impairment or dialysis (see Contraindications). Half-life is prolonged as renal function declines.
• Hepatic impairment: Data are limited; no specific dose adjustment has been established.
• Elderly: Pharmacokinetic studies have not shown clinically important differences in elderly patients; no dose adjustment is generally required based on age alone, though renal function should be assessed.
• Pediatric patients: Safety and efficacy of oral Fosfomax have not been established in children 12 years of age and under; see Pediatric Uses.
• Pregnancy and lactation: See the dedicated Pregnancy and Lactation section.
• Men: The single-dose regimen is studied and approved specifically in women; use in men is not established and would be considered off-label.

For uncomplicated cystitis, Fosfomax is typically given as a single dose; no additional doses are usually required. If symptoms do not resolve within 2-3 days, or if they recur, a physician should be consulted for reassessment rather than repeating the dose independently. When used off-label for prophylaxis or in hospital-directed regimens for complicated infections, duration is determined individually by the prescribing physician.

The oral granules of Fosfomax are not swallowed dry. Empty one sachet into a glass and dissolve completely in 3-4 ounces (approximately 90-120 mL) of cool (not hot) water; stir and drink the entire solution immediately after mixing. Do not prepare the solution in advance or store it for later use.

Fosfomycin is classified as an antibiotic, specifically a phosphonic acid derivative and urinary anti-infective agent.

Fosfomycin exerts its bactericidal effect by irreversibly inhibiting the bacterial enzyme enolpyruvyl transferase (MurA), which catalyzes an essential early step in bacterial cell wall (peptidoglycan) biosynthesis. This action, combined with reduced bacterial adherence to the uroepithelium, disrupts bacterial cell wall integrity and leads to bacterial cell death.

B

The safety and effectiveness of oral Fosfomax (Fosfomax tromethamine) have not been established in children 12 years of age and younger, and it is not FDA-approved for use in this age group. Use in adolescents and children should only occur under specialist pediatric guidance when no suitable alternative exists, with close monitoring. Parents/caregivers should not give Fosfomax to a child without a physician's specific instruction.